Similar articles

• Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.

  Estey EH, Kantarjian H, Keating M. Estey EH, et al. Semin Oncol. 1993 Dec;20(6 Suppl 8):1-5. Semin Oncol. 1993. PMID: 8290966 Clinical Trial.
• Treatment of myelodysplastic syndromes with AML-type chemotherapy.

  Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, Escudier S, Koller C, Kornblau S, Robertson L, et al. Estey E, et al. Leuk Lymphoma. 1993;11 Suppl 2:59-63. doi: 10.3109/10428199309064263. Leuk Lymphoma. 1993. PMID: 7510196 Clinical Trial. No abstract available.
• Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.

  Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G. Saure C, et al. Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29. Biol Blood Marrow Transplant. 2012. PMID: 21963618 Clinical Trial.
• Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.

  Hennessy B, Giles F, Cortes J, O'brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S. Hennessy B, et al. Am J Hematol. 2004 Nov;77(3):209-14. doi: 10.1002/ajh.20211. Am J Hematol. 2004. PMID: 15495258 Review.
• Idarubicin: an anthracycline antineoplastic agent.

  Cersosimo RJ. Cersosimo RJ. Clin Pharm. 1992 Feb;11(2):152-67. Clin Pharm. 1992. PMID: 1551297 Review.